NCT06566989View on ClinicalTrials.gov

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

October 17, 2024

Study Completion Date

October 17, 2024

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

[¹⁴C]Opevesostat

Oral solution

DRUG

Prednisone

Tablet

DRUG

Fludrocortisone

Tablet

Trial Locations (1)

NG11 6JS

Quotient Sciences ( Site 0001), Nottingham

All Listed Sponsors
collaborator

Orion Corporation, Orion Pharma

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06566989 - A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008) | Biotech Hunter | Biotech Hunter